Health Catalyst (HCAT) Cost of Revenue (2018 - 2026)

Health Catalyst (HCAT) has reported Cost of Revenue for 9 consecutive years, with $35.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 16.13% year-over-year to $35.6 million; the trailing twelve-month figure through Jun 2026 stood at $144.7 million (down 16.29% YoY), and the FY2025 full-year result was $159.5 million, down 3.83% from the prior year.
• Cost of Revenue climbed to $35.6 million in Q2 2026 per HCAT's latest filing, from $35.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $44.9 million in Q4 2024 and bottomed at $34.0 million in Q1 2022.
• Historically, Cost of Revenue has averaged $39.1 million across 5 years, with a median of $38.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue grew 24.35% in 2022, then slipped 21.42% in 2025.
• Over 5 years, Cost of Revenue stood at $38.1 million in 2022, then rose by 16.98% to $44.6 million in 2023, then grew by 0.76% to $44.9 million in 2024, then retreated by 21.42% to $35.3 million in 2025, then increased by 0.94% to $35.6 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $35.6 million, $35.3 million, and $35.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.